2026-03-21 02:46:13
Latest Post
Kiaasa Retail Ltd opens 4 retail outlets
NIS Facility Management Services Ltd receives order worth Rs. 56.01 lakhs
IndiQube Signs 1140 Seats Workspace Leasing Deal with Major GCC Client in Pune
Thomas Cook India Ltd announces the demerger of its Resorts and Resort Management business into Sterling Holiday Resorts Ltd
Vikram Solar appoints Sameer Nagpal as CEO to Lead Next Phase of Strategic Growth
Stock Report
NATCO Pharma Launches Semaglutide Generic Injection Multi Dose Vials in India at the Most Affordable Price Starting from MRP INR 1,290
Posted On : 2026-03-20 20:36:27( TIMEZONE : IST )
NATCO Pharma Limited (BSE: 524816 and NSE: NATCOPHARM) ("NATCO") announces launch of Semaglutide Injection (multi dose vials) in the India market tomorrow on Day 1 of patent expiry.
NATCO received Central Drugs Standard Control Organisation (CDSCO) approval to manufacture and market generic Semaglutide in India in February'26 for multi dose vials and pen device based on the clinical comparison study. Semaglutide is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise.
NATCO plans to launch Semaglutide injection in the form of multi dose vials of strengths 2mg/1.5ml, 4mg/3ml and 8mg/3ml under the brand names SEMANATTM and SEMAFULLTM. Multi dose vials will be launched at MRP of INR 1,290 per month for 2 mg/1.5ml & 4mg/3ml and MRP of INR 1,750 for 8mg/3ml.
Pen device will be priced at MRP of INR 4,000, INR 4,200 and INR 4,500 per month for the strengths 2mg/1.5ml, 4mg/3ml and 8mg/3ml respectively. Pen device is expected to be launched in April'26.
NATCO is the first company to offer generic Semaglutide in multi dose vials with customised syringes. NATCO is also offering the product to third parties for co-marketing.
NATCO is the first company to offer Semaglutide in the vial dosage form. It is the most affordable GLP-1 currently in the Indian market as it is approximately 70% cheaper in cost than the pen device and 90% cheaper than the price of the innovator's brand. This will increase patient accessibility to the GLP-1 therapy and would help in long term compliance for the patients.
Shares of Natco Pharma Limited was last trading in BSE at Rs. 957.85 as compared to the previous close of Rs. 937.05. The total number of shares traded during the day was 54909 in over 2265 trades.
The stock hit an intraday high of Rs. 973.00 and intraday low of 941.75. The net turnover during the day was Rs. 52813757.00.
